Chemomab Therapeutics Ltd. (CMMB)

Market Cap	23.55M
Revenue (ttm)	n/a
Net Income (ttm)	-15.00M
Shares Out	14.36M
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,775
Open	1.640
Previous Close	1.620
Day's Range	1.600 - 1.710
52-Week Range	0.420 - 2.550
Beta	0.30
Analysts	Strong Buy
Price Target	7.33 (+346.95%)
Earnings Date	Nov 14, 2024

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: CMMB
• Website: https://www.chemomab.com

Analyst Forecast

According to 3 analysts, the average rating for CMMB stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 346.95% from the latest price.

Price Target

$7.33

(346.95% upside)

Analyst Consensus: Strong Buy